FDA approves testing CBD for use in opioid addiction treatment
Earlier this month, FDA gave the green light for human testing of CBD for opioid addiction treatment, a step further for the industry. Since part of addiction treatment is the reduction of craving, CBD will be tested in its ability to lessen the craving of substances through the effects it has on eating behavior and pleasure.
Many CBD-derived product manufacturers claim the substance can effectively alleviate chronic pain, nausea, and other side effects from cancer treatment, and other medical conditions.
A joint study by the University of Chicago and the University of Louisville found that patients who took oral doses of CBD were less likely to get a positive COVID-19 test. However, the universities urged people not to use CBD as a treatment for the virus at this time.
CBD is quickly becoming an alternative to conventional remedies, thus opening the door to further medical research.
The ongoing adoption and legalization of CBD for medical ailments have been key for the North American market, which is estimated to grow from $15.2 billion in 2021 to $38.2 billion in 2028, per Research and Markets.
Posted by: Information Services Our Information Services team assists our clients with understanding commodity and ingredient market dynamics. Using our extensive database of intelligence, we also produce regular commodity and commercial market publications covering supply and demand fundamentals, news alerts on events that shape the markets, and resource guides to give you a complete picture of the industries we monitor.